Drug Makers Denounce Court Ruling Overturning Abortion Drug Approval
Industry executives, trade groups and medical organizations said the ruling undermines the US FDA, flies in the face of science and would harm innovation by drug makers if allowed to stand.
You may also be interested in...
What’s Next For FDA In Face Of Opposing Mifepristone Injunctions
Agency appeals Texas federal court decision staying its approval of the medication abortion pill. It is unclear how the ruling would be implemented if it stands, and what the impact might be from an opposing same-day order from another court for FDA to keep mifepristone available. Texas ruling could have significant consequences for industry, former FDA attorney says.
Merck Suggests More IO/ADC Combos To Come Under Oncology Strategy
The company laid out a three-pronged strategy focused on immuno-oncology, antibody-drug conjugates as well as small molecules, with four programs set to enter pivotal trials this year.
Regeneron, Pfizer Tout Potential BCMA Bispecific Advantages At ASCO
Regeneron presented data for linvoseltamab, while Pfizer presented data for elranatamab, including in patients who previously received BCMA-directed therapy.